Request Trial
11 September 2026NewsRegulation & IndustryMarisa Woutersen

Built to be bought? What makes companies acquisition-ready

For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Regulation & Industry
UK to clamp down on non-compete clauses and long notice periods
13 October 2026   Potential reforms to post-employment restrictions and contractual notice periods could make it harder for brand owners to protect trade secrets and manage staff departures, prompting questions about how businesses can safeguard their interests.
Regulation & Industry
AIPPI World Congress: ‘Diversity need not be an obstacle to unity’
9 October 2026   As the AIPPI World Congress returned to Germany for the first time in nearly half a century, it heard calls for greater international cooperation and legal harmonisation, highlighting why diversity matters for the future of IP and brand owners.
Regulation & Industry
5 LSPN takeaways: What’s keeping Europe’s IP teams on their toes?
1 October 2026   LSPN Europe made its Basel debut, and two days of conversations showed just how much is changing for life sciences professionals—both in how they work and what they are being asked to do. Marisa Woutersen tallies up the talking points.


Editor's picks

WATCH: Medmix global IP head on building business-focused IP teams
In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026

Editor's picks

In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026

More features

WATCH: Medmix global IP head on building business-focused IP teams
Fish & Richardson hires duo with ‘sophisticated’ tech patent expertise
Fed Circ refuses to rehear Insulet’s $59.4m trade secret loss
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
Align Technology notches another win in escalating clear aligner feud
Guardant loses second patent challenge to TwinStrand amid $245m damages fallout
Boehringer and Dr Reddy’s spar over plausibility as trial wraps up
Haynes Boone expands in California with new office